

# Appendix 3B

## New issue announcement, application for quotation of additional securities and agreement

*Information or documents not available now must be given to ASX as soon as available.  
Information and documents given to ASX become ASX's property and may be made public.*

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12

### Name of entity:

PRANA BIOTECHNOLOGY LIMITED (ASX: PBT)

### ABN:

37 080 699 065

We (the entity) give ASX the following information.

### Part 1 - All issues

*You must complete the relevant sections (attach sheets if there is not enough space).*

1	+Class of +securities issued or to be issued	a) Ordinary Shares b) Unlisted Options
2	Number of +securities issued or to be issued (if known) or maximum number which may be issued	a) 59,171,610 b) 1,200,000
3	Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)	a) Pari passu with existing Ordinary Shares (PBT) b) Unlisted Options exercisable at AUD\$0.25 on or before 6 April 2018

For personal use only

4	<p>Do the <sup>+</sup>securities rank equally in all respects from the date of allotment with an existing <sup>+</sup>class of quoted <sup>+</sup>securities?</p> <p>If the additional securities do not rank equally, please state:</p> <ul style="list-style-type: none"> <li>• the date from which they do</li> <li>• the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>• the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul>	<p>a) Yes (PBT)</p> <p>b) Yes, upon exercise of Ordinary Shares</p>
5	Issue price or consideration	<p>a) \$16,378,781</p> <p>b) Nil consideration – Options issued under ESOP</p>
6	<p>Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)</p>	<p>a) Including the exercise of 216,750 (PBTAI) Options, to fund the Company’s current clinical development, research programs and working capital (as part of an on-going placement).</p> <p>b) As per Employee Incentive Scheme and Consulting Agreements</p>
6a	<p>Is the entity an <sup>+</sup>eligible entity that has obtained security holder approval under rule 7.1A?</p> <p>If Yes, complete sections 6b – 6h <i>in relation to the <sup>+</sup>securities the subject of this Appendix 3B</i>, and comply with section 6i</p>	<p>Yes</p>
6b	The date the security holder resolution under rule 7.1A was passed	<p>28 November 2013</p>
6c	Number of <sup>+</sup> securities issued without security holder approval under rule 7.1	<p>a) 51,039,922</p>
6d	Number of <sup>+</sup> securities issued with security holder approval under rule 7.1A	<p>a) 6,914,938</p>
6e	Number of <sup>+</sup> securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	<p>a) 216,750</p>
6f	Number of securities issued under an exception in rule 7.2	<p>a) 1,000,000 shares</p> <p>b) 1,200,000 options</p>

6g	<p>If securities issued under rule 7.1A:</p> <ul style="list-style-type: none"> <li>• was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3?</li> <li>• Include the issue date,</li> <li>• and both values.</li> <li>• Include the source of the VWAP calculation.</li> </ul>	<ul style="list-style-type: none"> <li>• Yes</li> <li>• Issue date: 7 April 2014. <ul style="list-style-type: none"> <li>○ VWAP : \$0.4771</li> <li>○ Issue Price: \$0.3578 per share.</li> </ul> </li> <li>• Source of VWAP Calculation: IRESS</li> </ul>				
6h	<p>If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements</p>	<p>N/A</p>				
6i	<p>Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements</p>	<p>Refer annexure 1</p>				
7	<p>Dates of entering *securities into uncertificated holdings or despatch of certificates</p>	<p>3-7 April 2014</p>				
8	<p>Number and *class of all *securities quoted on ASX (<i>including</i> the securities in section 2 if applicable)</p>	<table border="1"> <thead> <tr> <th data-bbox="746 1032 1002 1070">Number</th> <th data-bbox="1002 1032 1425 1070">*Class</th> </tr> </thead> <tbody> <tr> <td data-bbox="746 1070 1002 1294">488,646,960</td> <td data-bbox="1002 1070 1425 1294">Ordinary Shares (PBT)</td> </tr> </tbody> </table>	Number	*Class	488,646,960	Ordinary Shares (PBT)
Number	*Class					
488,646,960	Ordinary Shares (PBT)					

- 9 Number and \*class of all \*securities not quoted on ASX (including the securities in section 2 if applicable)

ASX Code	Number	Class of Securities			Issued under an ESOP
		Security Type	Exercise Price	Expiry Date	
PBTAA	200,000	Unlisted Options	AUD\$0.61	24 Oct 2018	2004 ASX Plan
PBTAB	180,000	Unlisted Options	\$Nil	7 Aug 2014	2004 ASX Plan
PBTAC	1,649,573	Unlisted Options	AUD\$0.37	25 June 2018	2004 ASX Plan
PBTAD	360,000	Unlisted Options	AUD\$0.73	3 Nov 2018	2004 ASX Plan
PBTAE	1,200,000	Unlisted Options	AUD\$1.04	11 Dec 2018	2004 ASX Plan
PBTAF	300,000	Unlisted Options	AUD\$1.12	5 Feb 2019	2004 ASX Plan
PBTAI	2,166,995	Unlisted Options	AUD\$0.225	24 Mar 2015	-
PBTAO	612,397	Unlisted Options	AUD\$0.17	24 Feb 2016	-
PBTAQ	8,500,000	Unlisted Options	AUD\$0.33	13 Dec 2017	2004 ASX Plan
PBTAU	1,000,000	Unlisted Options	AUD\$0.25	19 Dec 2014	2004 ASX Plan
PBTAW	1,119,519	Unlisted Options	AUD\$0.25	20 Mar 2017	2004 ASX Plan
PBTAY	306,490	Unlisted Options	AUD\$0.66	4 Aug 2018	2004 ASX Plan
PBTAZ	360,000	Unlisted Options	AUD\$0.66	1 Oct 2018	2004 ASX Plan
New Class	1,200,000	Unlisted Options	AUD\$0.25	6 Apr 2018	2004 ASX Plan
<b>TOTAL</b>	<b>19,154,974</b>				

- 10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

Unchanged

## Part 2 - Bonus issue or pro rata issue

- 11 Is security holder approval required?
- 12 Is the issue renounceable or non-renounceable?
- 13 Ratio in which the \*securities will be offered
- 14 \*Class of \*securities to which the offer relates
- 15 \*Record date to determine entitlements
- 16 Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?
- 17 Policy for deciding entitlements in relation to fractions
- 18 Names of countries in which the entity has \*security holders who will not be sent new issue documents  
Note: Security holders must be told how their entitlements are to be dealt with.  
Cross reference: rule 7.7.
- 19 Closing date for receipt of acceptances or renunciations
- 20 Names of any underwriters
- 21 Amount of any underwriting fee or commission
- 22 Names of any brokers to the issue
- 23 Fee or commission payable to the broker to the issue
- 24 Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of \*security holders

For personal use only

- 25 If the issue is contingent on \*security holders' approval, the date of the meeting
- 26 Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled
- 27 If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders
- 28 Date rights trading will begin (if applicable)
- 29 Date rights trading will end (if applicable)
- 30 How do \*security holders sell their entitlements *in full* through a broker?
- 31 How do \*security holders sell *part* of their entitlements through a broker and accept for the balance?
- 32 How do \*security holders dispose of their entitlements (except by sale through a broker)?
- 33 \*Despatch date

### Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

- ✓
- 34 Type of securities  
(tick one)
    - (a)  Securities described in Part 1
    - (b)  All other securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

## Entities that have ticked box 34(a)

### Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

- 35  If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders
- 36  If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories  
 1 - 1,000  
 1,001 - 5,000  
 5,001 - 10,000  
 10,001 - 100,000  
 100,001 and over
- 37  A copy of any trust deed for the additional +securities

## Entities that have ticked box 34(b)

- 38 Number of securities for which +quotation is sought
- 39 Class of +securities for which quotation is sought
- 40 Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?  
  
 If the additional securities do not rank equally, please state:  
 • the date from which they do  
 • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  
 • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment
- 41 Reason for request for quotation now (if issued upon conversion of another security, clearly identify that other security)  
  
 Example: In the case of restricted securities, end of restriction period
- 42 Number and +class of all +securities quoted on ASX (including the securities in clause 38)
- | Number | +Class |
|--------|--------|
|        |        |

For personal use only

## Quotation Agreement

1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.

2 We warrant the following to ASX.


- The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
- There is no reason why those +securities should not be granted +quotation.
- An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.



Sign Here:

\_\_\_\_\_  
Company Secretary

Date: Monday 7<sup>th</sup> April 2014

Print Name: Mr Richard Revelins



**The CFO Solution**

07.04.2014

For personal use only



# Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for <sup>+</sup> eligible entities

Introduced 01/08/12

### Part 1

Rule 7.1 – Issues exceeding 15% of capital	
<b>Step 1: Calculate “A”, the base figure from which the placement capacity is calculated</b>	
<b>Insert</b> number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue	344,143,038
<b>Add</b> the following: <ul style="list-style-type: none"> <li>• Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>• Number of fully paid ordinary securities issued in that 12 month period with shareholder approval</li> <li>• Number of partly paid ordinary securities that became fully paid in that 12 month period</li> </ul>	<div style="display: flex; flex-direction: column; gap: 10px;"> <div style="text-align: right;">15,952,872</div> <div style="text-align: right;">58,801,500</div> <div style="text-align: right;">Nil</div> </div>
<b>Note:</b> <ul style="list-style-type: none"> <li>• Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>• Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>• It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	
<b>Subtract</b> the number of fully paid ordinary securities cancelled during that 12 month period	Nil
<b>“A”</b>	418,897,410
<b>Step 2: Calculate 15% of “A”</b>	
<b>“B”</b>	0.15 <i>[Note: this value cannot be changed]</i>
<b>Multiply “A”</b> by 0.15	62,834,612

For personal use only

For personal use only

<b>Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used</b>	
<p><b>Insert</b> number of equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:</p> <ul style="list-style-type: none"> <li>• Under an exception in rule 7.2</li> <li>• Under rule 7.1A</li> <li>• With security holder approval under rule 7.1 or rule 7.4</li> </ul> <p><b>Note:</b></p> <ul style="list-style-type: none"> <li>• <i>This applies to equity securities, unless specifically excluded – not just ordinary securities</i></li> <li>• <i>Include here (if applicable ) the securities the subject of the Appendix 3B to which this form is annexed</i></li> <li>• <i>It may be useful to set out issues of securities on different dates as separate line items</i></li> </ul>	62,834,612
<b>"C"</b>	<b>62,834,612</b>

<b>Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1</b>	
<p>"A" x 0.15</p> <p><i>Note: number must be same as shown in Step 2</i></p>	62,834,612
<p><b>Subtract "C"</b></p> <p><i>Note: number must be same as shown in Step 3</i></p>	62,834,612
<p><b>Total</b> ["A" x 0.15] – "C"</p>	<p>0</p> <p><i>[Note: this is the remaining placement capacity under rule 7.1]</i></p>

## Part 2

### Rule 7.1A – Additional placement capacity for eligible entities

#### Step 1: Calculate “A”, the base figure from which the placement capacity is calculated

<b>“A”</b> <i>Note: number must be same as shown in Step 1 of Part 1</i>	418,897,410
---	-------------

#### Step 2: Calculate 10% of “A”

<b>“D”</b>	0.10 <i>Note: this value cannot be changed</i>
<b>Multiply “A” by 0.10</b>	41,889,741

#### Step 3: Calculate “E”, the amount of placement capacity under rule 7.1A that has already been used

<b>Insert</b> number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A  <i>Notes:</i> <ul style="list-style-type: none"> <li>• This applies to equity securities – not just ordinary securities</li> <li>• Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>• Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>• It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	6,914,938
<b>“E”</b>	<b>6,914,938</b>

#### Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A

<b>“A” x 0.10</b> <i>Note: number must be same as shown in Step 2</i>	41,889,741
<b>Subtract “E”</b> <i>Note: number must be same as shown in Step 3</i>	6,914,938
<b>Total [“A” x 0.10] – “E”</b>	34,974,803  <i>Note: this is the remaining placement capacity under rule 7.1A</i>

For personal use only

## ASX ANNOUNCEMENT

### Information disclosed under LR 3.10.5A and 7.1A.4(b) [ASX Code: PBT]

Prana advises that 58,171,610 New Ordinary Shares have been issued via the 'At The Market' (ATM) facility operating in the US and 1,000,000 New Ordinary Shares have been issued under the ESOP, in total raising approximately A\$16,378,781.

Of the total 59,171,610 shares issued today; 6,914,938 were issued under listing rule 7.1A raising A\$2,474,317.

Prana will continue to make use of a variety of financing options in order to take its lead compound, PBT2, to market over the coming years. These options include Capital Raisings, Government Grants, Private Grants, Tax Rebate Programs, Licencing agreements and the ATM facility.

The following information is disclosed under ASX LR 3.10.5A in relation to the 6,914,938 securities issued under LR 7.1A.

**a) Details of dilution to the existing holders of ordinary securities caused by the issue.**

	Pre placement Qty, including issued under LR7.1 and LR7.2	% of Qty issued	Qty issued under LR 7.1A	Total issued Shares post LR7.1A issue	% of post LR7.1A issue held
Qty of ordinary shares held by existing shareholders participating in issue	-	-	-	-	-
Qty of ordinary shares held by existing shareholders not participating in the LR7.1A issue	481,732,022	-	-	481,732,022	98.58%
Qty of ordinary shares issued to new shareholders under the LR7.1A issue	-	1.44%	6,914,938	6,914,938	1.42%
<b>Total ordinary shares</b>	<b>481,732,022</b>	<b>1.44%</b>	<b>6,914,938</b>	<b>488,646,960</b>	<b>100%</b>

- b) Where the equity securities were issued for cash consideration, a statement of the reasons why the issue was made under LR 7.1A and not as another type of issue which existing ordinary security holders would have been eligible to participate.**

Due to the cost and timing benefits the funds have been raised utilising the Company's ATM facility in the US. The funds will be used to accelerate the regulatory pathway of its key clinical asset PBT2.

- c) Details of any underwriting arrangements, including fees payable to the underwriter.**

No underwriting arrangements were entered into.

- d) Any other fees or costs incurred in connection with the issue.**

The Company incurred a broker commission fee equal to 3% of funds raised.

For and on behalf of the Company,



Richard Revelins  
Company Secretary

## Cleansing Statement

### Notice Under Section 708A(5) of the Corporations Act [ASX Code: PBT]

**Monday 7<sup>th</sup> April 2014**

This notice is given under paragraph (5)(e) of section 708A of the Corporations Act.

<b>Type:</b>	Ordinary Shares
<b>Class/Description:</b>	Ordinary Fully Paid Shares
<b>ASX Code:</b>	PBT
<b>Date of Issue:</b>	3-7 April 2014
<b>Number Issued:</b>	59,171,610
<b>Issue Price:</b>	AUD\$16,378,781

Accordingly the Company gives notice under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (the "Corporations Act") that:

1. the abovementioned ordinary shares were issued without disclosure to investors under Part 6D.2 of the *Corporations Act*;
2. as at the date of this notice the Company has complied with:
  - (i) the provisions of Chapter 2M *Corporations Act* as they apply to the Company; and
  - (ii) section 674 *Corporations Act*; and
3. as at the date of this notice there is no "excluded information" (as defined in subsection 708A(7) of the Corporations Act) which is required to be disclosed by the Company.

For and on behalf of the Company,



Richard Revelins  
Company Secretary  
Prana Biotechnology Limited

For personal use only